Hôpital Roger Salengro, CHRU de Lille
Lille, France
NCT Number: NCT03651362
This study evaluates the length of optic nerve lesion on 3D-DIR sequence as an imaging biomarker predictive of retinal axonal loss and visual disability, 12 months after the occurence of a first clinical episode of optic neuritis.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Observational
Lille, France
Neurologists and Neuro-Ophthalmologists are in need for reliable and robust imaging biomarkers enabling to predict retinal axonal loss and visual disability after clinical episode of optic neuritis (ON). Length of optic nerve lesion measured on MRI may be one of them.
The aim of our study is to measure the association between the extent of inflammatory demyelinating process on optic nerve at the acute of ON and the retinal degenerative process following optic nerve injury.
The investigators planned to include 50 patients suffering from a recent clinical episode of ON.
Extent of demyelinating inflammatory process will be assessed by the length of optic nerve double inversion recovery (DIR) hypersignal at the acute phase of ON.
The axonal degenerative process following optic nerve demyelinating injury will be assessed by retinal atrophy measured on optical coherence tomography at 12 months after ON, by visual disability measured on low vision contrast acuity scale and by microstructural quality analysis of optic nerve measured on diffusion tensor imaging sequence of the optic nerve.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 12 months
peripapillary RNFL thickness decrease
Time frame: 12 months
macular volume decrease
Time frame: 12 months
monocular low contrast (2.5%) vision
Time frame: 12 months
fractional anisotropy
Time frame: 12 months
lesion length in mm measured on 3D-double inversion recovery sequence
University Hospital, Lille
Other
Linking Optic Nerve Lesion Length at MRI and the Retinal Axonal Loss at 12 Months From a Clinical Episode of Optic Neuritis
Acronym: IRMANO
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04289909
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Paris, France
View Trial DetailsNCT03451955
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Copenhagen, Frederiksberg, Denmark
View Trial DetailsNCT01274702
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Berlin, Germany
View Trial DetailsNCT04792866
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Paris, Île-de-France Region, France
View Trial Details